Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents

Join us for this dynamic, CME/CNE/CPE-certified symposium! At this event, an expert panel will discuss pressing complex questions in CLL treatment across the disease spectrum, and provide a look ahead at new data and promising agents that may soon change practice.

Sign up now! Registration is complimentary.

This session is open to all health care providers attending the congress; pre-registration is not required. CME/CNE/CPE available. This symposium is accredited and supported separately from all other educational sessions on the general session agenda. Seating is limited and on a first-come, first-seated basis.

Agenda

12:10 – 12:15 PM    Welcome and Introduction

12:15 – 12:20 PM    Overview of CLL Diagnosis and Evaluation

12:20 – 12:40 PM    Case-based Discussion in Newly Diagnosed CLL

12:40 – 1:00 PM      Case-based Discussion in Previously Treated CLL

1:00 – 1:05 PM        Promising Agents and Combinations Regimens Under
                                 Investigation

1:05 – 1:10 PM        Audience Question and Answer Session

Faculty

Faculty
Jeremy Abramson, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Faculty
William G. Wierda, MD, PhD

Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this program is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who treat and manage patients with chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Consider the efficacy and safety profile of the therapeutic agent along with patient characteristics and molecular features of CLL to individualize therapeutic strategies for newly diagnosed CLL
  • Choose optimal treatment for relapsed/refractory CLL based on the available clinical data, guidelines, and expert recommendations
  • Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life
  • Evaluate the efficacy, toxicity profile and other practical management considerations associated with novel approved and investigational agents and combination regimens in CLL
  • Manage adverse events associated with treatment approaches for CLL to ensure treatment compliance to improve clinical outcomes and quality of life

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hours.

Pharmacists

NCCN designates this knowledge-based continuing education activity for 1.0 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-9999-19-xxxxx

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.